Skip to content

Menu

Contributions
- Poster ED. 2022
- Scientific Contributions
  ED. 2022
About us
News
Gallery
Contacts

IBD

SATURDAY 16 MARCH, 11:30 SESSION II
Chair: Angelo Gratarola; Vincenzo Cantaluppi

IBD

P40

AVE-UC (Apheresys and Vedolizumab in Ulcerative Colitis) study.
Combination therapy with leukocytoapheresys and Vedolizumab in patients with ulcerative colitis refractory to anti-TNFsM CappelloPalermo

P41

Efficacy and safety of leukocytapheresis adsorber device LA25: experience with 9 patientsA Ferronato; K I Rodriguez-Castro; E Zanetti; G Errigo; F Sola; G Baldassarre SantorsoVicenza

P42

Combination therapy with leukocytoapheresys and Vedolizumab in a
patient with ulcerative colitis refractory to anti-TNFsM Cappello; B Scrivo and A CraxìPalermo

Poster Ed. 2022
Scientific Contributions
ED. 2022
Scientific Contributions
Ed. 2019
Poster Ed. 2019
Scientific Contributions
Ed. 2017
Poster Ed. 2017

SESSION POSTER I

SIRS, sepsis and MODS

Cardiac surgery and ECMO

SESSION POSTER II

Pediatric patients

Immunological pathologies

© Aferetica s.r.l. P.I./VAT 03330561204 - sito web a cura di BauWeb

The information posted here by Aferetica Srl or any third party are dedicated to health professionals.The information posted here does not represent the advertising aimed at personnel not belonging to healthcare field.Aferetica disclaims any responsibility for the use of this website information by professionals non belonging to healthcare field. By using this website, the visitor declares to be a health professional and to accept these terms and conditions.

This website does NOT use any profiling cookie to send you advertising in line with your preferences. Only technical cookies are used. There may be third-party cookies related to videos, maps or social plugins. If you want to know more about the use of cookies on this website and read how to disable them, please read our Cookies Policy. If you access any site element, you consent to cookies to this website.I Agree More Info